Dec 30 (Reuters) - Sangamo Therapeutics SGMO.O said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer PFE.N terminated the agreement.
(Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed Safi Shamsi)
((Puyaan.Singh@thomsonreuters.com;))